CKD-MBD - a commonly overlooked complication in our patient population
And one of the most under-prescribed drug (atleast in India) in the armamentarium is Cinacalcet
Here's a short thread on calcimimetics #medtweetorial#nephtweetorial#iqraakidneyclub
Mechanism of action?
As the name says -- a 'calcium' mimetic
Makes the CaSR in the parathyroid gland feel there's 'too much' calcium and suppresses PTH
How is it different from Active Vitamin D analogues?
While both aim to suppress PTH, their actions on Ca x P and FGF 23 levels are different
This could turn out to positively effect mortality outcomes? Let's find out
No conversation on Cinacalcet can go without bringing up EVOLVE.
A large multicenter RCT with a mortality outcome.
BUT 1. Though the study was negative, mortality rates adjusted to baseline to baseline was significant 2. Subgroup analysis with age >65 showed mortality benefit
And finally, the new drugs on the list - Evolcalcet and Etelcalcetide.
Please tell me why are they spelt so tough 🤷♂️
While the more potent Etelcalcetide comes with more severe hypocalcemia but lower GI a/e, the weaker Evolcalcet comes with the least side effects
With no solid RCT with a positive outcome (yet), it is still questionable to prescribe the drug in and out.
That and the high cost (considering I work at a low-resource setting).
That leads to one question - what would be your clinical indication to start one on a calcimimetic?
• • •
Missing some Tweet in this thread? You can try to
force a refresh
BKVAN is a 2-hit disease - with 1) local environmental factors in the kidney (IRI, ureteral injury during transplant) and 2) immunosuppression playing a key role
Risk factors can be donor/recipient/procedure/virus-related:
Local factors are the reason why: 1) BKVAN can occur quite early in transplant 2) BKVAN is more common in renal than other solid organ transplants